All News

RheumNow Podcast square

EULAR 2026 Rheumatology RoundUp

Jack Cush, MD

It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.

Read Article
manpower.cliff.shortage

Rheumatology Shortage Cliff in Australia & USA

Jack Cush, MD

Australia is facing a deepening rheumatology manpower crisis with direct parallels to the situation in the United States.

Read Article
drug%20interactions.jpg

Increased Polypharmacy in SLE Patients

Jack Cush, MD

A cross-sectional study of US adults with systemic lupus erythematosus (SLE) shows significantly increased prevalence of polypharmacy, related to age, disease outcomes and often, non-SLE common medications.

Read Article
Sjogren's on chalkboard

RepurpSS-II: Hydroxychloroquine plus Leflunomide in Sjögren's

Jack Cush, MD

A small, pilot, phase 2b trial has shown that the combination of leflunomide and hydroxychloroquine (LEF+HCQ) was effective and safe in treating patients with active Sjögren's disease.

Read Article
lupus.nephritis.immunofluorescence.jpg

Trends and Innovations in Lupus Nephritis Clinical Trials

Jack Cush, MD

Xu et al. from Shanghai University have written an analysis of global lupus nephritis (LN) clinical trials and call for innovation.

Read Article
SLE Pipeline of New Therapies Dr. Andrea Fava, EULAR 2026 in London. https://t.co/GwntaPwzWr https://t.co/prFnaSKuqF

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.

Dr. John Cush RheumNow ( View Tweet)

All content is independently chosen and produced by the RheumNow faculty. Our expanded #EULAR2026 coverage is made possible by support from Bristol Myers Squibb and UCB.

Dr. John Cush RheumNow ( View Tweet)

RheumNow’s expanded coverage of #EULAR2026 annual meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.

Dr. John Cush RheumNow ( View Tweet)

JAK Safety Debate Continues: Stronger VTE signal, less clear cancer signal Few topics in rheumatology have reshaped prescribing behaviour as dramatically as the safety concerns surrounding JAK inhibitors following ORAL Surveillance and the subsequent FDA and EMA warnings. https://t.co/mvTRRL7srA
Dr. John Cush RheumNow ( View Tweet)
Not all #RA pts respond equally to advanced therapy. 10-variable risk model >18k US pts: low baseline disease activity, fewer comorbidities, and no prior biologics 5x more likely to achieve remission at 1yr (34% vs 7%). RWD for precision care @RheumNow #EULAR2026 POS0257

Jiha Lee JihaRheum ( View Tweet)

Our expanded #EULAR2026 coverage is made possible by support from Bristol Myers Squibb and UCB. All content is independently chosen and produced by the RheumNow faculty.

Dr. John Cush RheumNow ( View Tweet)

Looking forward to CAR T cell therapy trials in #SSc Phase 2 and 3 studies presented at #HOT session by Pr Oliver Distler #CAR_T #EULAR2026 @RheumNow https://t.co/bmXZpF2wKg

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
JAK Safety Debate Continues: Stronger VTE signal, less clear cancer signal Few topics in rheumatology have reshaped prescribing behavior as dramatically as the safety concerns surrounding JAK inhibitors following ORAL Surveillance and the subsequent FDA and EMA warnings. Even https://t.co/wfQZn1hO3N
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.

Dr. John Cush RheumNow ( View Tweet)

Review of Ruxolitinib in 7 pts w/ refractory systemic JIA complicated by macrophage activation (MAS) (ages 1.6-11 yrs; 3M: 4F). 5 achieved complete remission; 2 partial remission. 2 relapsed w/ GC tapering (remission after adding canakinumab). No deaths https://t.co/j4Cm3UYB9c https://t.co/pKoDwpSKII

Links:

Dr. John Cush RheumNow ( View Tweet)
LRA Awards for Immune Resetting Therapies in Lupus LRA, the world’s largest private funder of lupus research, in collaboration with Genentech, a member of the Roche Group, announced the inaugural recipients of the Lupus Research Alliance-Genentech Award on Immune Resetting https://t.co/eDAq17lhM0
Dr. John Cush RheumNow ( View Tweet)
Trends and Innovations in Lupus Nephritis Clinical Trials Xu et al. from Shanghai University have written an analysis of global lupus nephritis (LN) clinical trials and call for innovation. This systematic review of was informed by 200 interventional pharmacological trials https://t.co/fUTIMhMAis
Dr. John Cush RheumNow ( View Tweet)
RHEUM SURVEY> Per 2024 EULAR Guidelines, an active RA pt on MTX who fails a 1st TNFi, should next change to ?

Dr. John Cush RheumNow ( View Tweet)

BE BOLD Week 16 data - Bimekizumab vs. Risankizumab in PsA UCB has released the Week 16 results from BE BOLD trial that will be presented at EULAR 2026 in London on Saturday, June 6. This head-to-head trial demonstrates that at week 16, bimekizumab (BKZ) yielded superior ACR50 https://t.co/VVBaNdWIuQ
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×